Repertoire Immune Medicines landed a licensing deal with Roche-owned Genentech worth up to $765 million to develop an autoimmune treatment.
Why it matters: Boston-based Repertoire isn't done fundraising, with additional partnerships or an IPO on its road map, CEO Torben Straight Nissen tells Axios.
